Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Leukemia & Lymphoma | August 7, 2020 | Volume: 61 | Issue: 13 | Pages: 3188-3197
10.1080/10428194.2020.1795159
| PMID 32762271